128 results on '"S. Jane Henley"'
Search Results
2. COVID-19 and Other Underlying Causes of Cancer Deaths — United States, January 2018–July 2022
- Author
-
S Jane, Henley, Nicole F, Dowling, Farida B, Ahmad, Taylor D, Ellington, Manxia, Wu, and Lisa C, Richardson
- Subjects
Health (social science) ,Health Information Management ,Epidemiology ,Health, Toxicology and Mutagenesis ,General Medicine - Abstract
Cancer survivors (persons who have received a diagnosis of cancer, from the time of diagnosis throughout their lifespan)* have increased risk for severe COVID-19 illness and mortality (1). This report describes characteristics of deaths reported to CDC's National Vital Statistics System (NVSS), for which cancer was listed as the underlying or a contributing cause (cancer deaths) during January 1, 2018-July 2, 2022. The underlying causes of death, including cancer and COVID-19, were examined by week, age, sex, race and ethnicity, and cancer type. Among an average of approximately 13,000 weekly cancer deaths, the percentage with cancer as the underlying cause was 90% in 2018 and 2019, 88% in 2020, and 87% in 2021. The percentage of cancer deaths with COVID-19 as the underlying cause differed by time (2.0% overall in 2020 and 2.4% in 2021, ranging from 0.2% to 7.2% by week), with higher percentages during peaks in the COVID-19 pandemic. The percentage of cancer deaths with COVID-19 as the underlying cause also differed by the characteristics examined, with higher percentages observed in 2021 among persons aged ≥65 years (2.4% among persons aged 65-74 years, 2.6% among persons aged 75-84 years, and 2.4% among persons aged ≥85 years); males (2.6%); persons categorized as non-Hispanic American Indian or Alaska Native (AI/AN) (3.4%), Hispanic or Latino (Hispanic) (3.2%), or non-Hispanic Black or African American (Black) (2.5%); and persons with hematologic cancers, including leukemia (7.4%), lymphoma (7.3%), and myeloma (5.8%). This report found differences by age, sex, race and ethnicity, and cancer type in the percentage of cancer deaths with COVID-19 as the underlying cause. These results might guide multicomponent COVID-19 prevention interventions and ongoing, cross-cutting efforts to reduce health disparities and address structural and social determinants of health among cancer survivors, which might help protect those at disproportionate and increased risk for death from COVID-19.
- Published
- 2022
3. Trends in breast cancer mortality by race/ethnicity, age, and US census region, United States─1999‐2020
- Author
-
Taylor D. Ellington, S. Jane Henley, Reda J. Wilson, Jacqueline W. Miller, Manxia Wu, and Lisa C. Richardson
- Subjects
Cancer Research ,Oncology - Abstract
Breast cancer remains a leading cause of morbidity and mortality among women in the United States. Previous analyses show that breast cancer incidence increased from 1999 to 2018. The purpose of this article is to examine trends in breast cancer mortality.Analysis of 1999 to 2020 mortality data from the Centers for Disease Control and Prevention, National Center for Health Statistics, among women by race/ethnicity, age, and US Census region.It was found that overall breast cancer mortality is decreasing but varies by race/ethnicity, age group, and US Census region. The largest decrease in mortality was observed among non-Hispanic White women, women aged 45 to 64 years of age, and women living in the Northeast; whereas the smallest decrease in mortality was observed among non-Hispanic Asian or Pacific Islander women, women aged 65 years or older, and women living in the South.This report provides national estimates of breast cancer mortality from 1999 to 2020 by race/ethnicity, age group, and US Census region. The decline in breast cancer mortality varies by demographic group. Disparities in breast cancer mortality have remained consistent over the past two decades. Using high-quality cancer surveillance data to estimate trends in breast cancer mortality may help health care professionals and public health prevention programs tailor screening and diagnostic interventions to address these disparities.
- Published
- 2022
4. Annual report to the nation on the status of cancer, part 1: National cancer statistics
- Author
-
Kathleen A. Cronin, Susan Scott, Albert U. Firth, Hyuna Sung, S. Jane Henley, Recinda L. Sherman, Rebecca L. Siegel, Robert N. Anderson, Betsy A. Kohler, Vicki B. Benard, Serban Negoita, Charles Wiggins, William G. Cance, and Ahmedin Jemal
- Subjects
Male ,American Cancer Society ,Cancer Research ,Lung Neoplasms ,Adolescent ,Incidence ,United States ,National Cancer Institute (U.S.) ,Young Adult ,Oncology ,Neoplasms ,Humans ,Female ,Child ,Melanoma ,Early Detection of Cancer - Abstract
The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States.Data on new cancer diagnoses during 2001-2018 were obtained from the North American Association of Central Cancer Registries' Cancer in North America Incidence file, which is comprised of data from Centers for Disease Control and Prevention-funded and National Cancer Institute-funded, population-based cancer registry programs. Data on cancer deaths during 2001-2019 were obtained from the National Center for Health Statistics' National Vital Statistics System. Five-year average incidence and death rates along with trends for all cancers combined and for the leading cancer types are reported by sex, racial/ethnic group, and age.Overall cancer incidence rates were 497 per 100,000 among males (ranging from 306 among Asian/Pacific Islander males to 544 among Black males) and 431 per 100,000 among females (ranging from 309 among Asian/Pacific Islander females to 473 among American Indian/Alaska Native females) during 2014-2018. The trend during the corresponding period was stable among males and increased 0.2% on average per year among females, with differing trends by sex, racial/ethnic group, and cancer type. Among males, incidence rates increased for three cancers (including pancreas and kidney), were stable for seven cancers (including prostate), and decreased for eight (including lung and larynx) of the 18 most common cancers considered in this analysis. Among females, incidence rates increased for seven cancers (including melanoma, liver, and breast), were stable for four cancers (including uterus), and decreased for seven (including thyroid and ovary) of the 18 most common cancers. Overall cancer death rates decreased by 2.3% per year among males and by 1.9% per year among females during 2015-2019, with the sex-specific declining trend reflected in every major racial/ethnic group. During 2015-2019, death rates decreased for 11 of the 19 most common cancers among males and for 14 of the 20 most common cancers among females, with the steepest declines (4% per year) reported for lung cancer and melanoma. Five-year survival for adenocarcinoma and neuroendocrine pancreatic cancer improved between 2001 and 2018; however, overall incidence (2001-2018) and mortality (2001-2019) continued to increase for this site. Among children (younger than 15 years), recent trends were stable for incidence and decreased for mortality; and among, adolescents and young adults (aged 15-39 years), recent trends increased for incidence and declined for mortality.Cancer death rates continued to decline overall, for children, and for adolescents and young adults, and treatment advances have led to accelerated declines in death rates for several sites, such as lung and melanoma. The increases in incidence rates for several common cancers in part reflect changes in risk factors, screening test use, and diagnostic practice. Racial/ethnic differences exist in cancer incidence and mortality, highlighting the need to understand and address inequities. Population-based incidence and mortality data inform prevention, early detection, and treatment efforts to help reduce the cancer burden in the United States.
- Published
- 2022
5. Pairing Project ECHO and patient navigation as an innovative approach to improving the health and wellness of cancer survivors in rural settings
- Author
-
Elizabeth Rohan, Nora Kuiper, Shelly‐Ann Bowen, Dana Keener Mast, Marnie House, Cynthia French, Felicia Solomon Tharpe, S. Jane Henley, Ena Wanliss, and Mary Puckett
- Subjects
Rural Population ,Cancer Survivors ,Neoplasms ,Public Health, Environmental and Occupational Health ,Humans ,Patient Navigation ,Pilot Projects - Abstract
We conducted a 12-month pilot study of 2 complementary strategies for improving rural cancer survivorship outcomes: (1) Project ECHO, a telementoring model to increase knowledge and skills about cancer survivorship among multidisciplinary health care provider teams in rural areas and (2) patient navigation (PN) services to connect rural cancer survivors with resources for enhancing health and wellness.We recruited 4 CDC-funded National Comprehensive Cancer Control Program sites to implement Project ECHO and PN interventions for a defined rural population in each of their jurisdictions. Sites received ongoing technical assistance and a stipend to support implementation. We conducted a mixed-methods evaluation consisting of quantitative performance monitoring data and qualitative interviews with site staff to assess implementation.Site teams delivered 21 cancer survivorship ECHO sessions to rural providers resulting in 329 participant encounters. Almost all (93%) ECHO participants reported enhanced knowledge of cancer survivorship issues, and 80% reported intent to apply learnings to their practices. Site teams engaged 16 patient navigators who navigated 164 cancer survivors during the study period. Successful implementation required strong partnerships, clear avenues for recruitment of rural providers and cancer survivors, and activities tailored to local needs. Fostering ongoing relationships among sites through community of practice calls also enhanced implementation.Sites successfully implemented a novel approach for enhancing care for cancer survivors in rural communities. Pairing Project ECHO to address structural barriers and PN to address individual factors affecting survivorship may help bridge the health equity gap experienced by cancer survivors in rural communities.
- Published
- 2022
6. Data from Multilevel Small-Area Estimation of Multiple Cigarette Smoking Status Categories Using the 2012 Behavioral Risk Factor Surveillance System
- Author
-
James Holt, S. Jane Henley, Lucy Peipins, Thomas B. Richards, Xingyou Zhang, and Zahava Berkowitz
- Abstract
Background: Smoking is the leading preventable cause of death; however, small-area estimates for detailed smoking status are limited. We developed multilevel small-area estimate mixed models to generate county-level estimates for six smoking status categories: current, some days, every day, former, ever, and never.Method: Using 2012 Behavioral Risk Factor Surveillance System (BRFSS) data (our sample size = 405,233 persons), we constructed and fitted a series of multilevel logistic regression models and applied them to the U.S. Census population to generate county-level prevalence estimates. We mapped the estimates by sex and aggregated them into state and national estimates. We conducted comparisons for internal consistency with BRFSS states' estimates using Pearson correlation coefficients, and external validation with the 2012 National Health Interview Survey current smoking prevalence.Results: Correlation coefficients ranged from 0.908 to 0.982, indicating high internal consistency. External validation indicated complete agreement (prevalence = 18.06%). We found large variations in current and former smoking status between and within states and by sex. County prevalence of former smokers was highest among men in the Northeast, North, and West. Utah consistently had the lowest smoking prevalence.Conclusions: Our models, which include demographic and geographic characteristics, provide reliable estimates that can be applied to multiple category outcomes and any demographic group. County and state estimates may help understand the variation in smoking prevalence in the United States and provide information for control and prevention.Impact: Detailed county and state smoking category estimates can help identify areas in need of tobacco control and prevention and potentially allow planning for health care. Cancer Epidemiol Biomarkers Prev; 25(10); 1402–10. ©2016 AACR.
- Published
- 2023
7. Supplementary Methods and Materials from Multilevel Small-Area Estimation of Multiple Cigarette Smoking Status Categories Using the 2012 Behavioral Risk Factor Surveillance System
- Author
-
James Holt, S. Jane Henley, Lucy Peipins, Thomas B. Richards, Xingyou Zhang, and Zahava Berkowitz
- Abstract
Supplementary Methods and Materials
- Published
- 2023
8. Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care
- Author
-
Recinda L. Sherman, Jingxuan Zhao, Hyuna Sung, S. Jane Henley, Elizabeth Ward, Florence K. L. Tangka, Angela B. Mariotto, K. Robin Yabroff, Farhad Islami, and Ahmedin Jemal
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,MEDLINE ,Cancer ,Pharmacy ,Disease ,medicine.disease ,Confidence interval ,Oncology ,Epidemiology ,medicine ,Medical prescription ,Medical Expenditure Panel Survey ,business ,Demography - Abstract
Background The American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries provide annual information about cancer occurrence and trends in the United States. Part 1 of this annual report focuses on national cancer statistics. This study is part 2, which quantifies patient economic burden associated with cancer care. Methods We used complementary data sources, linked Surveillance, Epidemiology, and End Results-Medicare, and the Medical Expenditure Panel Survey to develop comprehensive estimates of patient economic burden, including out-of-pocket and patient time costs, associated with cancer care. The 2000-2013 Surveillance, Epidemiology, and End Results-Medicare data were used to estimate net patient out-of-pocket costs among adults aged 65 years and older for the initial, continuing, and end-of-life phases of care for all cancer sites combined and separately for the 21 most common cancer sites. The 2008-2017 Medical Expenditure Panel Survey data were used to calculate out-of-pocket costs and time costs associated with cancer among adults aged 18-64 years and 65 years and older. Results Across all cancer sites, annualized net out-of-pocket costs for medical services and prescriptions drugs covered through a pharmacy benefit among adults aged 65 years and older were highest in the initial ($2200 and $243, respectively) and end-of-life phases ($3823 and $448, respectively) and lowest in the continuing phase ($466 and $127, respectively), with substantial variation by cancer site. Out-of-pocket costs were generally higher for patients diagnosed with later-stage disease. Net annual time costs associated with cancer were $304.3 (95% confidence interval = $257.9 to $350.9) and $279.1 (95% confidence interval = $215.1 to $343.3) for adults aged 18-64 years and ≥65 years, respectively, with higher time costs among more recently diagnosed survivors. National patient economic burden, including out-of-pocket and time costs, associated with cancer care was projected to be $21.1 billion in 2019. Conclusions This comprehensive study found that the patient economic burden associated with cancer care is substantial in the United States at the national and patient levels.
- Published
- 2021
9. Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years — United States, August 2020–August 2021
- Author
-
Jennifer Adjemian, Elizabeth B Gray, David A. Siegel, Joy Hsu, Joyce Dalton, Andrea J Cool, Elliot Raizes, Linda Mattocks, Amitabh B. Suthar, Katharina L. van Santen, Kanta Sircar, Pavithra Natarajan, Karl Soetebier, Cheryl R. Cornwell, Georgina Peacock, Sapna Bamrah Morris, Tegan K. Boehmer, Pamela Logan, Kathleen P. Hartnett, Beth Schweitzer, B Casey Lyons, Kimberly Lochner, Osatohamwen Idubor, Hannah E. Reses, Cria G. Perrine, S. Jane Henley, Eghosa Oyegun, Michael Sheppard, Michael C. Martin, and Craig N. Shapiro
- Subjects
Pediatrics ,medicine.medical_specialty ,COVID-19 Vaccines ,Vaccination Coverage ,Health (social science) ,Adolescent ,Epidemiology ,Health, Toxicology and Mutagenesis ,Disease ,Severity of Illness Index ,law.invention ,Health Information Management ,law ,Pandemic ,Severity of illness ,medicine ,Humans ,Full Report ,Child ,business.industry ,Infant, Newborn ,COVID-19 ,Infant ,General Medicine ,Emergency department ,Intensive care unit ,United States ,Hospitalization ,Vaccination ,El Niño ,Child, Preschool ,Diagnosis code ,Emergency Service, Hospital ,business ,Facilities and Services Utilization - Abstract
Although COVID-19 generally results in milder disease in children and adolescents than in adults, severe illness from COVID-19 can occur in children and adolescents and might require hospitalization and intensive care unit (ICU) support (1-3). It is not known whether the B.1.617.2 (Delta) variant,* which has been the predominant variant of SARS-CoV-2 (the virus that causes COVID-19) in the United States since late June 2021, causes different clinical outcomes in children and adolescents compared with variants that circulated earlier. To assess trends among children and adolescents, CDC analyzed new COVID-19 cases, emergency department (ED) visits with a COVID-19 diagnosis code, and hospital admissions of patients with confirmed COVID-19 among persons aged 0-17 years during August 1, 2020-August 27, 2021. Since July 2021, after Delta had become the predominant circulating variant, the rate of new COVID-19 cases and COVID-19-related ED visits increased for persons aged 0-4, 5-11, and 12-17 years, and hospital admissions of patients with confirmed COVID-19 increased for persons aged 0-17 years. Among persons aged 0-17 years during the most recent 2-week period (August 14-27, 2021), COVID-19-related ED visits and hospital admissions in the states with the lowest vaccination coverage were 3.4 and 3.7 times that in the states with the highest vaccination coverage, respectively. At selected hospitals, the proportion of COVID-19 patients aged 0-17 years who were admitted to an ICU ranged from 10% to 25% during August 2020-June 2021 and was 20% and 18% during July and August 2021, respectively. Broad, community-wide vaccination of all eligible persons is a critical component of mitigation strategies to protect pediatric populations from SARS-CoV-2 infection and severe COVID-19 illness.
- Published
- 2021
10. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
- Author
-
S. Jane Henley, Ahmedin Jemal, Florence K. L. Tangka, Recinda L. Sherman, K. Robin Yabroff, Robert N. Anderson, Vicki B. Benard, Elizabeth Ward, Farhad Islami, Kathleen A. Cronin, Jingxuan Zhao, and Hyuna Sung
- Subjects
Male ,Cancer Research ,Lung Neoplasms ,Adolescent ,Population ,Breast Neoplasms ,Young Adult ,Neoplasms ,medicine ,Humans ,Registries ,Young adult ,Child ,Lung cancer ,education ,Melanoma ,American Cancer Society ,education.field_of_study ,Relative survival ,business.industry ,Incidence ,Mortality rate ,Incidence (epidemiology) ,Editorials ,Cancer ,Articles ,medicine.disease ,United States ,National Cancer Institute (U.S.) ,Cancer registry ,Editor's Choice ,Oncology ,Population Surveillance ,Female ,business ,AcademicSubjects/MED00010 ,SEER Program ,Demography - Abstract
Background The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries collaborate to provide annual updates on cancer incidence and mortality and trends by cancer type, sex, age group, and racial/ethnic group in the United States. In this report, we also examine trends in stage-specific survival for melanoma of the skin (melanoma). Methods Incidence data for all cancers from 2001 through 2017 and survival data for melanoma cases diagnosed during 2001-2014 and followed-up through 2016 were obtained from the Centers for Disease Control and Prevention- and National Cancer Institute-funded population-based cancer registry programs compiled by the North American Association of Central Cancer Registries. Data on cancer deaths from 2001 to 2018 were obtained from the National Center for Health Statistics’ National Vital Statistics System. Trends in age-standardized incidence and death rates and 2-year relative survival were estimated by joinpoint analysis, and trends in incidence and mortality were expressed as average annual percent change (AAPC) during the most recent 5 years (2013-2017 for incidence and 2014-2018 for mortality). Results Overall cancer incidence rates (per 100 000 population) for all ages during 2013-2017 were 487.4 among males and 422.4 among females. During this period, incidence rates remained stable among males but slightly increased in females (AAPC = 0.2%, 95% confidence interval [CI] = 0.1% to 0.2%). Overall cancer death rates (per 100 000 population) during 2014-2018 were 185.5 among males and 133.5 among females. During this period, overall death rates decreased in both males (AAPC = −2.2%, 95% CI = −2.5% to −1.9%) and females (AAPC = −1.7%, 95% CI = −2.1% to −1.4%); death rates decreased for 11 of the 19 most common cancers among males and for 14 of the 20 most common cancers among females, but increased for 5 cancers in each sex. During 2014-2018, the declines in death rates accelerated for lung cancer and melanoma, slowed down for colorectal and female breast cancers, and leveled off for prostate cancer. Among children younger than age 15 years and adolescents and young adults aged 15-39 years, cancer death rates continued to decrease in contrast to the increasing incidence rates. Two-year relative survival for distant-stage skin melanoma was stable for those diagnosed during 2001-2009 but increased by 3.1% (95% CI = 2.8% to 3.5%) per year for those diagnosed during 2009-2014, with comparable trends among males and females. Conclusions Cancer death rates in the United States continue to decline overall and for many cancer types, with the decline accelerated for lung cancer and melanoma. For several other major cancers, however, death rates continue to increase or previous declines in rates have slowed or ceased. Moreover, overall incidence rates continue to increase among females, children, and adolescents and young adults. These findings inform efforts related to prevention, early detection, and treatment and for broad and equitable implementation of effective interventions, especially among under resourced populations.
- Published
- 2021
11. Feasibility of visualizing cancer incidence data at sub-county level: Findings from 21 National Program of Cancer Registries
- Author
-
Taylor D. Ellington, Angela K. Werner, S. Jane Henley, Lisa E. Paddock, and Pamela K. Agovino
- Subjects
Infectious Diseases ,Epidemiology ,Health, Toxicology and Mutagenesis ,Geography, Planning and Development - Published
- 2023
12. Cancer survival in the United States 2007–2016: Results from the National Program of Cancer Registries
- Author
-
Taylor D. Ellington, S. Jane Henley, Reda J. Wilson, Virginia Senkomago, Manxia Wu, Vicki Benard, and Lisa C. Richardson
- Subjects
Multidisciplinary - Abstract
Background Cancer survival has improved for the most common cancers. However, less improvement and lower survival has been observed in some groups perhaps due to differential access to cancer care including prevention, screening, diagnosis, and treatment. Methods To further understand contemporary relative cancer survival (one- and five- year), we used survival data from CDC’s National Program of Cancer Registries (NPCR) for cancers diagnosed during 2007–2016. We examined overall relative cancer survival by sex, race and ethnicity, age, and county-level metropolitan and non-metropolitan status. Relative cancer survival by metropolitan and non-metropolitan status was further examined by sex, race and ethnicity, age, and cancer type. Results Among persons with cancer diagnosed during 2007–2016 the overall one-year and five-year relative survival was 80.6% and 67.4%, respectively. One-year relative survival for persons living in metropolitan counties was 81.1% and 77.8% among persons living in non-metropolitan counties. We found that persons who lived in non-metropolitan counties had lower survival than those who lived in metropolitan counties, and this difference persisted across sex, race and ethnicity, age, and most cancer types. Conclusion Further examination of the differences in cancer survival by cancer type or other characteristics might be helpful for identifying potential interventions, such as programs that target screening and early detection or strategies to improve access to high quality cancer treatment and follow-up care, that could improve long-term outcomes. Impact This analysis provided a high-level overview of contemporary cancer survival in the United States.
- Published
- 2023
13. Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐2016
- Author
-
Reda J. Wilson, Taylor D Ellington, S. Jane Henley, Manxia Wu, and Lisa C. Richardson
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Time Factors ,Rural Health ,0302 clinical medicine ,immune system diseases ,Risk Factors ,hemic and lymphatic diseases ,Plasma Cell Myeloma ,Epidemiology ,Multiple myeloma ,Original Research ,Aged, 80 and over ,education.field_of_study ,Incidence (epidemiology) ,Mortality rate ,Incidence ,Age Factors ,Hispanic or Latino ,Middle Aged ,Race Factors ,myeloma ,Oncology ,030220 oncology & carcinogenesis ,cancer surveillance ,epidemiology ,Female ,Multiple Myeloma ,Cancer Prevention ,Adult ,medicine.medical_specialty ,Population ,Risk Assessment ,White People ,03 medical and health sciences ,Young Adult ,Sex Factors ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Obesity ,education ,American Indian or Alaska Native ,Aged ,business.industry ,Racial Groups ,Urban Health ,Cancer ,medicine.disease ,United States ,Black or African American ,030104 developmental biology ,business ,Solitary plasmacytoma ,Plasmacytoma - Abstract
Plasma cell myeloma (also called multiple myeloma), solitary plasmacytoma, and extramedullary plasmacytoma are primarily diseases of the elderly. Evidence suggests an association between excess body weight and multiple myeloma. Few population‐based studies have examined incidence and mortality of each site in one study. We analyzed incidence and death rates by site (solitary plasmacytoma, extramedullary plasmacytoma, and multiple myeloma) by gender, age, race/ethnicity, and rural‐urban status among adult males and females (aged 20 years or older) in the United States during 2003‐2016. Trends were characterized as average annual percentage change (AAPC) in rates. During 2003‐2016, overall incidence rates among adults were 0.45 for solitary plasmacytoma, 0.09 for extramedullary plasmacytoma, and 8.47 for multiple myeloma per 100,000 persons. Incidence rates for multiple myeloma increased during 2003‐2016 among non‐Hispanic whites (AAPC = 1.78%) and non‐Hispanic blacks (2.98%) 20‐49 years of age; non‐Hispanic whites (1.17%) and non‐Hispanic blacks (1.24%) 50‐59 years of age; and whites non‐Hispanic (0.91%), and non‐Hispanic blacks (0.96%). During 2003‐2016 overall myeloma (extramedullary plasmacytoma and multiple myeloma) death rates among adults was 4.77 per 100,00 persons. Myeloma death rates decreased during 2003‐2016 among non‐Hispanic white (AAPC = −1.23%) and Hispanic (−1.34%) women; and non‐Hispanic white (−0.74%), non‐Hispanic American Indian/Alaska Native (−3.05%) men. The US population is projected to become older and will have a larger proportion of persons who have had an earlier and longer exposure to excess body weight. The potential impact of these population changes on myeloma incidence and mortality can be monitored with high‐quality cancer surveillance data., Plasma cell myeloma (also called multiple myeloma), solitary plasmacytoma, and extramedullary plasmacytoma are primarily diseases of the elderly. Few population‐based studies have examined incidence and mortality of each site in one study. We analyzed incidence and death rates by site (solitary plasmacytoma, extramedullary plasmacytoma, and multiple myeloma) by gender, age, race/ethnicity, and rural‐urban status among adult males and females (aged 20 years or older) in the United States during 2003‐2016.
- Published
- 2020
14. Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 — United States, May–August 2020
- Author
-
Zeyu Li, Jennifer Fuld, Farida B. Ahmad, Phillip P. Salvatore, S. Jane Henley, Kenneth L. Dominguez, Francis B Annor, Brendan R Jackson, Tonji Durant, Jeremy A W Gold, Brittney N. Baack, Jennifer DeCuir, Deborah L. Dee, Paul D Sutton, Jayme P Coyle, Achuyt Bhattarai, and Lauren M. Rossen
- Subjects
medicine.medical_specialty ,Race ethnicity ,Health (social science) ,Census Region ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,business.industry ,Health, Toxicology and Mutagenesis ,Public health ,010102 general mathematics ,Ethnic group ,General Medicine ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Public health surveillance ,Pandemic ,Medicine ,030212 general & internal medicine ,0101 mathematics ,Young adult ,business ,Demography - Abstract
During February 12-October 15, 2020, the coronavirus disease 2019 (COVID-19) pandemic resulted in approximately 7,900,000 aggregated reported cases and approximately 216,000 deaths in the United States.* Among COVID-19-associated deaths reported to national case surveillance during February 12-May 18, persons aged ≥65 years and members of racial and ethnic minority groups were disproportionately represented (1). This report describes demographic and geographic trends in COVID-19-associated deaths reported to the National Vital Statistics System† (NVSS) during May 1-August 31, 2020, by 50 states and the District of Columbia. During this period, 114,411 COVID-19-associated deaths were reported. Overall, 78.2% of decedents were aged ≥65 years, and 53.3% were male; 51.3% were non-Hispanic White (White), 24.2% were Hispanic or Latino (Hispanic), and 18.7% were non-Hispanic Black (Black). The number of COVID-19-associated deaths decreased from 37,940 in May to 17,718 in June; subsequently, counts increased to 30,401 in July and declined to 28,352 in August. From May to August, the percentage distribution of COVID-19-associated deaths by U.S. Census region increased from 23.4% to 62.7% in the South and from 10.6% to 21.4% in the West. Over the same period, the percentage distribution of decedents who were Hispanic increased from 16.3% to 26.4%. COVID-19 remains a major public health threat regardless of age or race and ethnicity. Deaths continued to occur disproportionately among older persons and certain racial and ethnic minorities, particularly among Hispanic persons. These results can inform public health messaging and mitigation efforts focused on prevention and early detection of infection among disproportionately affected groups.
- Published
- 2020
15. Breast Cancer Survival Among Males by Race, Ethnicity, Age, Geographic Region, and Stage — United States, 2007–2016
- Author
-
Jacqueline W. Miller, Taylor D Ellington, Reda J. Wilson, and S. Jane Henley
- Subjects
Male ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Ethnic group ,Disease ,01 natural sciences ,Breast Neoplasms, Male ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Breast cancer ,Health Information Management ,Ethnicity ,medicine ,Humans ,Full Report ,030212 general & internal medicine ,0101 mathematics ,Stage (cooking) ,Survival analysis ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Geography ,Relative survival ,business.industry ,Racial Groups ,010102 general mathematics ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,United States ,Male breast cancer ,business ,Demography - Abstract
Breast cancer among males in the United States is rare; approximately 2,300 new cases and 500 associated deaths were reported in 2017, accounting for approximately 1% of all breast cancers.* Risk for male breast cancer increases with increasing age (1), and compared with women, men receive diagnoses later in life and often at a later stage of disease (1). Gradual improvement in breast cancer survival from 1976-1985 to 1996-2005 has been more evident for women than for men (1). Studies examining survival differences among female breast cancer patients observed that non-Hispanic White (White) females had a higher survival than non-Hispanic Black (Black) females (2), but because of the rarity of breast cancer among males, few studies have examined survival differences by race or other factors such as age, stage, and geographic region. CDC's National Program of Cancer Registries (NPCR)† data were used to examine relative survival of males with breast cancer diagnosed during 2007-2016 by race/ethnicity, age group, stage at diagnosis, and U.S. Census region. Among males who received a diagnosis of breast cancer during 2007-2016, 1-year relative survival was 96.1%, and 5-year relative survival was 84.7%. Among characteristics examined, relative survival varied most by stage at diagnosis: the 5-year relative survival for males was higher for cancers diagnosed at localized stage (98.7%) than for those diagnosed at distant stage (25.9%). Evaluation of 1-year and 5-year relative survival among males with breast cancer might help guide health care decisions regarding early detection of male breast cancer and establishing programs to support men at high risk for breast cancer and male breast cancer survivors.
- Published
- 2020
16. Carcinogens and Toxicants in Smokeless Tobacco Products
- Author
-
S. Jane Henley, Taylor Ellington, Stephen Stanfill, Kathi Mills, and Michael J. Thun
- Published
- 2022
17. Cancers Associated with Human Papillomavirus in American Indian and Alaska Native Populations — United States, 2013–2017
- Author
-
Stephanie C. Melkonian, S. Jane Henley, Virginia Senkomago, Cheryll C. Thomas, Melissa A. Jim, Andria Apostolou, and Mona Saraiya
- Subjects
Male ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Vulva ,Health Information Management ,Neoplasms ,Cancer screening ,medicine ,Humans ,Registries ,Full Report ,Papillomaviridae ,biology ,business.industry ,Incidence ,Incidence (epidemiology) ,Papillomavirus Infections ,Cancer ,General Medicine ,Alaskan Natives ,Anus ,biology.organism_classification ,medicine.disease ,United States ,Cancer registry ,Vaccination ,medicine.anatomical_structure ,Indians, North American ,Female ,business ,Demography - Abstract
Human papillomavirus (HPV) causes most cervical cancers and some cancers of the penis, vulva, vagina, oropharynx, and anus. Cervical precancers can be detected through screening. HPV vaccination with the 9-valent HPV vaccine (9vHPV) can prevent approximately 92% of HPV-attributable cancers (1).* Previous studies have shown lower incidence of HPV-associated cancers in non-Hispanic American Indian and Alaska Native (AI/AN) populations compared with other racial subgroups (2); however, these rates might have been underestimated as a result of racial misclassification. Previous studies have shown that cancer registry data corrected for racial misclassification resulted in more accurate cancer incidence estimates for AI/AN populations (3,4). In addition, regional variations in cancer incidence among AI/AN populations suggest that nationally aggregated data might not adequately describe cancer outcomes within these populations (5). These variations might, in part, result from geographic disparities in the use of health services, such as cancer screening or vaccination (6). CDC analyzed data for 2013-2017 from central cancer registries linked with the Indian Health Service (IHS) patient registration database to assess the incidence of HPV-associated cancers and to estimate the number of cancers caused by HPV among AI/AN populations overall and by region. During 2013-2017, an estimated 1,030 HPV-associated cancers were reported in AI/AN populations. Of these cancers, 740 (72%) were determined to be attributable to HPV types targeted by 9vHPV; the majority were cervical cancers in females and oropharyngeal cancers in males. These data can help identify regions where AI/AN populations have disproportionately high rates of HPV-associated cancers and inform targeted regional vaccination and screening programs in AI/AN communities.
- Published
- 2020
18. Trends in Incidence of Cancers of the Oral Cavity and Pharynx — United States 2007–2016
- Author
-
Taylor D Ellington, Reda J. Wilson, Virginia Senkomago, S. Jane Henley, Mary Elizabeth O'Neil, Manxia Wu, Cheryll C. Thomas, Simple D. Singh, and Lisa C. Richardson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,01 natural sciences ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,Health Information Management ,Risk Factors ,Tongue ,otorhinolaryngologic diseases ,medicine ,Humans ,Full Report ,030212 general & internal medicine ,0101 mathematics ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,Soft palate ,business.industry ,Incidence ,Incidence (epidemiology) ,010102 general mathematics ,Pharynx ,Pharyngeal Neoplasms ,General Medicine ,Middle Aged ,Cheek ,Dermatology ,United States ,stomatognathic diseases ,medicine.anatomical_structure ,Tonsil ,Female ,Mouth Neoplasms ,Hard palate ,business - Abstract
Cancers of the oral cavity and pharynx account for 3% of cancers diagnosed in the United States* each year. Cancers at these sites can differ anatomically and histologically and might have different causal factors, such as tobacco use, alcohol use, and infection with human papillomavirus (HPV) (1). Incidence of combined oral cavity and pharyngeal cancers declined during the 1980s but began to increase around 1999 (2,3). Because tobacco use has declined in the United States, accompanied by a decrease in incidence of many tobacco-related cancers, researchers have suggested that the increase in oral cavity and pharynx cancers might be attributed to anatomic sites with specific cell types in which HPV DNA is often found (4,5). U.S. Cancer Statistics† data were analyzed to examine trends in incidence of cancers of the oral cavity and pharynx by anatomic site, sex, race/ethnicity, and age group. During 2007-2016, incidence rates increased for cancers of the oral cavity and pharynx combined, base of tongue, anterior tongue, gum, tonsil, oropharynx, and other oral cavity and pharynx. Incidence rates declined for cancers of the lip, floor of mouth, soft palate and uvula, hard palate, hypopharynx, and nasopharynx, and were stable for cancers of the cheek and other mouth and salivary gland. Ongoing implementation of proven population-based strategies to prevent tobacco use initiation, promote smoking cessation, reduce excessive alcohol use, and increase HPV vaccination rates might help prevent cancers of the oral cavity and pharynx.
- Published
- 2020
19. Annual report to the nation on the status of cancer, part I: National cancer statistics
- Author
-
S. Jane Henley, Elizabeth M. Ward, Susan Scott, Jiemin Ma, Robert N. Anderson, Albert U. Firth, Cheryll C. Thomas, Farhad Islami, Hannah K. Weir, Denise Riedel Lewis, Recinda L. Sherman, Manxia Wu, Vicki B. Benard, Lisa C. Richardson, Ahmedin Jemal, Kathleen Cronin, and Betsy A. Kohler
- Subjects
American Cancer Society ,Male ,Sex Characteristics ,Cancer Research ,Incidence ,National Cancer Institute (U.S.) ,United States ,Article ,Cross-Sectional Studies ,Oncology ,Neoplasms ,Humans ,Female ,Registries ,Centers for Disease Control and Prevention, U.S ,Mortality - Abstract
The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States.Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention-funded and National Cancer Institute-funded population-based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012-2016 for incidence and 2013-2017 for mortality).Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non-Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017.Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population-based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals.
- Published
- 2020
20. Annual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers
- Author
-
Vicki B. Benard, Recinda L. Sherman, Elizabeth Ward, Jiemin Ma, Hannah K. Weir, Manxia Wu, Susan Scott, Farhad Islami, Lisa C. Richardson, Betsy A. Kohler, Kathleen A. Cronin, Denise Riedel Lewis, Ahmedin Jemal, Cheryll C. Thomas, and S. Jane Henley
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Psychological intervention ,Breast Neoplasms ,Article ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Environmental health ,Cancer screening ,Epidemiology ,Humans ,Medicine ,Registries ,030212 general & internal medicine ,Mortality ,Early Detection of Cancer ,American Cancer Society ,Cancer prevention ,business.industry ,Prostatic Neoplasms ,Cancer ,medicine.disease ,National Cancer Institute (U.S.) ,United States ,Oncology ,Healthy People Programs ,030220 oncology & carcinogenesis ,Smoking cessation ,Female ,Centers for Disease Control and Prevention, U.S ,Rural area ,Colorectal Neoplasms ,business ,Lung cancer screening - Abstract
BACKGROUND The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States and to address a special topic of interest. Part I of this report focuses on national cancer statistics, and part 2 characterizes progress in achieving select Healthy People 2020 cancer objectives. METHODS For this report, the authors selected objectives-including death rates, cancer screening, and major risk factors-related to 4 common cancers (lung, colorectal, female breast, and prostate). Baseline values, recent values, and the percentage change from baseline to recent values were examined overall and by select sociodemographic characteristics. Data from national surveillance systems were obtained from the Healthy People 2020 website. RESULTS Targets for death rates were met overall and in most sociodemographic groups, but not among males, blacks, or individuals in rural areas, although these groups did experience larger decreases in rates compared with other groups. During 2007 through 2017, cancer death rates decreased 15% overall, ranging from -4% (rural) to -22% (metropolitan). Targets for breast and colorectal cancer screening were not yet met overall or in any sociodemographic groups except those with the highest educational attainment, whereas lung cancer screening was generally low (
- Published
- 2020
21. Screening for Lung Cancer — 10 States, 2017
- Author
-
Lisa C. Richardson, Ashwini Soman, Cheryll C. Thomas, Thomas B. Richards, M. Shayne Gallaway, Brenna VanFrank, and S. Jane Henley
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,01 natural sciences ,Cigarette Smoking ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Internal medicine ,Health care ,Humans ,Medicine ,Full Report ,030212 general & internal medicine ,0101 mathematics ,Stage (cooking) ,Lung cancer ,Early Detection of Cancer ,Aged ,Aged, 80 and over ,Lung ,Behavioral Risk Factor Surveillance System ,business.industry ,010102 general mathematics ,General Medicine ,Middle Aged ,medicine.disease ,United States ,Annual Screening ,medicine.anatomical_structure ,Practice Guidelines as Topic ,Smoking cessation ,Smoking Cessation ,business ,Lung cancer screening - Abstract
Lung cancer is the leading cause of cancer death in the United States; 148,869 lung cancer-associated deaths occurred in 2016 (1). Mortality might be reduced by identifying lung cancer at an early stage when treatment can be more effective (2). In 2013, the U.S. Preventive Services Task Force (USPSTF) recommended annual screening for lung cancer with low-dose computed tomography (CT) for adults aged 55-80 years who have a 30 pack-year* smoking history and currently smoke or have quit within the past 15 years (2).† This was a Grade B recommendation, which required health insurance plans to cover lung cancer screening as a preventive service.§ To assess the prevalence of lung cancer screening by state, CDC used Behavioral Risk Factor Surveillance System (BRFSS) data¶ collected in 2017 by 10 states.** Overall, 12.7% adults aged 55-80 years met the USPSTF criteria for lung cancer screening. Among those meeting USPSTF criteria, 12.5% reported they had received a CT scan to check for lung cancer in the last 12 months. Efforts to educate health care providers and provide decision support tools might increase recommended lung cancer screening.
- Published
- 2020
22. Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry
- Author
-
D. Kevin Horton, Dennis Deapen, Kristin J. Cummings, Marjorie G. Zauderer, David N. Weissman, S. Jane Henley, Michael J. Becich, Xiao-Cheng Wu, Emanuela Taioli, Mary Hesdorffer, Harvey I. Pass, Robert Harrison, Jacek M. Mazurek, David J. Blackley, and Raffit Hassan
- Subjects
medicine.medical_specialty ,Disease ,Article ,03 medical and health sciences ,0302 clinical medicine ,Standard care ,Humans ,Medicine ,Applied research ,Registries ,030212 general & internal medicine ,Mesothelioma ,business.industry ,Mesothelioma, Malignant ,Public Health, Environmental and Occupational Health ,Prognosis ,medicine.disease ,030210 environmental & occupational health ,United States ,Occupational Diseases ,Clinical trial ,Data sharing ,Deidentification ,Group discussion ,Population Surveillance ,Family medicine ,Feasibility Studies ,business - Abstract
The burden and prognosis of malignant mesothelioma in the United States have remained largely unchanged for decades, with approximately 3200 new cases and 2400 deaths reported annually. To address care and research gaps contributing to poor outcomes, in March of 2019 the Mesothelioma Applied Research Foundation convened a workshop on the potential usefulness and feasibility of a national mesothelioma registry. The workshop included formal presentations by subject matter experts and a moderated group discussion. Workshop participants identified top priorities for a registry to be (a) connecting patients with high-quality care and clinical trials soon after diagnosis, and (b) making useful data and biospecimens available to researchers in a timely manner. Existing databases that capture mesothelioma cases are limited by factors such as delays in reporting, deidentification, and lack of exposure information critical to understanding as yet unrecognized causes of disease. National disease registries for amyotrophic lateral sclerosis (ALS) in the United States and for mesothelioma in other countries, provide examples of how a registry could be structured to meet the needs of patients and the scientific community. Small-scale pilot initiatives should be undertaken to validate methods for rapid case identification, develop procedures to facilitate patient access to guidelines-based standard care and investigational therapies, and explore approaches to data sharing with researchers. Ultimately, federal coordination and funding will be critical to the success of a National Mesothelioma Registry in improving mesothelioma outcomes and preventing future cases of this devastating disease.
- Published
- 2019
23. Lung Cancer Incidence in Nonmetropolitan and Metropolitan Counties — United States, 2007–2016
- Author
-
Mary Elizabeth O'Neil, S. Jane Henley, Taylor D Ellington, Elizabeth A. Rohan, and M. Shayne Gallaway
- Subjects
Adult ,Male ,Rural Population ,Lung Neoplasms ,Health (social science) ,Urban Population ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,medicine.disease_cause ,01 natural sciences ,Asbestos ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Risk Factors ,medicine ,Humans ,Full Report ,030212 general & internal medicine ,0101 mathematics ,Lung cancer ,education ,Aged ,education.field_of_study ,Lung ,business.industry ,Incidence ,Incidence (epidemiology) ,010102 general mathematics ,Cancer ,Health Status Disparities ,General Medicine ,Middle Aged ,respiratory system ,medicine.disease ,Metropolitan area ,United States ,respiratory tract diseases ,medicine.anatomical_structure ,Female ,Residence ,business ,Demography - Abstract
Lung and bronchus (lung) cancer is the leading cause of cancer death in the United States (1). In 2016, 148,869 lung cancer deaths were reported.* Most lung cancers can be attributed to modifiable exposures, such as tobacco use, secondhand smoke, radon, and asbestos (1). Exposure to lung cancer risk factors vary over time and by characteristics such as sex, age, and nonmetropolitan or metropolitan residence that might affect lung cancer rates (1,2). A recent report found that lung cancer incidence rates were higher and decreased more slowly in nonmetropolitan counties than in metropolitan counties (3). To examine whether lung cancer incidence trends among nonmetropolitan and metropolitan counties differed by age and sex, CDC analyzed data from U.S. Cancer Statistics during 2007-2016, the most recent years for which data are available. During the 10-year study period, lung cancer incidence rates were stable among females aged
- Published
- 2019
24. Counties with High COVID-19 Incidence and Relatively Large Racial and Ethnic Minority Populations - United States, April 1-December 22, 2020
- Author
-
Florence C Lee, Sean M. Griffing, Sierra J Graves, Noah Aleshire, Leandris Liburd, Ana Penman-Aguilar, Jennifer Fuld, Michelle Van Handel, Laura Adams, Francis B Annor, Laura Mattocks, S. Jane Henley, Renee M Calanan, Tonji Durant, and Greta M. Massetti
- Subjects
medicine.medical_specialty ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,Ethnic group ,01 natural sciences ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Ethnicity ,Medicine ,Humans ,030212 general & internal medicine ,Full Report ,0101 mathematics ,education ,Health policy ,Minority Groups ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Public health ,Incidence ,010102 general mathematics ,Racial Groups ,COVID-19 ,General Medicine ,Health Status Disparities ,Health equity ,United States ,Epidemiological Monitoring ,Pacific islanders ,business ,Demography - Abstract
Long-standing systemic social, economic, and environmental inequities in the United States have put many communities of color (racial and ethnic minority groups) at increased risk for exposure to and infection with SARS-CoV-2, the virus that causes COVID-19, as well as more severe COVID-19-related outcomes (1-3). Because race and ethnicity are missing for a proportion of reported COVID-19 cases, counties with substantial missing information often are excluded from analyses of disparities (4). Thus, as a complement to these case-based analyses, population-based studies can help direct public health interventions. Using data from the 50 states and the District of Columbia (DC), CDC identified counties where five racial and ethnic minority groups (Hispanic or Latino [Hispanic], non-Hispanic Black or African American [Black], non-Hispanic Asian [Asian], non-Hispanic American Indian or Alaska Native [AI/AN], and non-Hispanic Native Hawaiian or other Pacific Islander [NH/PI]) might have experienced high COVID-19 impact during April 1-December 22, 2020. These counties had high 2-week COVID-19 incidences (>100 new cases per 100,000 persons in the total population) and percentages of persons in five racial and ethnic groups that were larger than the national percentages (denoted as "large"). During April 1-14, a total of 359 (11.4%) of 3,142 U.S. counties reported high COVID-19 incidence, including 28.7% of counties with large percentages of Asian persons and 27.9% of counties with large percentages of Black persons. During August 5-18, high COVID-19 incidence was reported by 2,034 (64.7%) counties, including 92.4% of counties with large percentages of Black persons and 74.5% of counties with large percentages of Hispanic persons. During December 9-22, high COVID-19 incidence was reported by 3,114 (99.1%) counties, including >95% of those with large percentages of persons in each of the five racial and ethnic minority groups. The findings of this population-based analysis complement those of case-based analyses. In jurisdictions with substantial missing race and ethnicity information, this method could be applied to smaller geographic areas, to identify communities of color that might be experiencing high potential COVID-19 impact. As areas with high rates of new infection change over time, public health efforts can be tailored to the needs of communities of color as the pandemic evolves and integrated with longer-term plans to improve health equity.
- Published
- 2021
25. Uterine Cancer Incidence and Mortality — United States, 1999–2016
- Author
-
Jacqueline W. Miller, Nicole F. Dowling, Lisa C. Richardson, S. Jane Henley, and Vicki B. Benard
- Subjects
medicine.medical_specialty ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Overweight ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Uterine cancer ,Ethnicity ,medicine ,Humans ,Neoplasm Invasiveness ,Vaginal bleeding ,Full Report ,Registries ,Uterine Neoplasm ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics ,Incidence ,Mortality rate ,Incidence (epidemiology) ,Racial Groups ,Cancer ,Health Status Disparities ,General Medicine ,medicine.disease ,United States ,Menopause ,030220 oncology & carcinogenesis ,Uterine Neoplasms ,Female ,medicine.symptom ,business - Abstract
Uterine cancer is one of the few cancers with increasing incidence and mortality in the United States, reflecting, in part, increases in the prevalence of overweight and obesity since the 1980s (1). It is the fourth most common cancer diagnosed and the seventh most common cause of cancer death among U.S. women (1). To assess recent trends in uterine cancer incidence and mortality by race and ethnicity, CDC analyzed incidence data from CDC's National Program of Cancer Registries (NPCR) and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and mortality data from the National Vital Statistics System (2). Most recent data available are through 2015 for incidence and through 2016 for mortality. Uterine cancer incidence rates increased 0.7% per year during 1999-2015, and death rates increased 1.1% per year during 1999-2016, with smaller increases observed among non-Hispanic white (white) women than among women in other racial/ethnic groups. In 2015, a total of 53,911 new uterine cancer cases, corresponding to 27 cases per 100,000 women, were reported in the United States, and 10,733 uterine cancer deaths (five deaths per 100,000 women) were reported in 2016. Uterine cancer incidence was higher among non-Hispanic black (black) and white women (27 cases per 100,000) than among other racial/ethnic groups (19-23 per 100,000). Uterine cancer deaths among black women (nine per 100,000) were higher than those among other racial/ethnic groups (four to five per 100,000). Public health efforts to help women achieve and maintain a healthy weight and obtain sufficient physical activity can reduce the risk for developing cancer of the endometrium (the lining of the uterus), the most common uterine cancer. Abnormal vaginal bleeding, including bleeding between periods or after sex or any unexpected bleeding after menopause, is an important symptom of uterine cancer (3). Through programs such as CDC's Inside Knowledge* campaign, promoting awareness among women and health care providers of the need for timely evaluation of abnormal vaginal bleeding can increase the chance that uterine cancer is detected early and treated appropriately.
- Published
- 2018
26. Surveillance for Cancers Associated with Tobacco Use — United States, 2010–2014
- Author
-
Cheryll C. Thomas, S. Jane Henley, Simple D. Singh, Katrina F. Trivers, Sherri L. Stewart, Behnoosh Momin, M. Shayne Gallaway, C. Brooke Steele, and Ahmed Jamal
- Subjects
Surgeon general ,Adult ,Male ,medicine.medical_specialty ,Health (social science) ,Epidemiology ,Colorectal cancer ,Health, Toxicology and Mutagenesis ,Population ,03 medical and health sciences ,Tobacco Use ,0302 clinical medicine ,Age Distribution ,Health Information Management ,Internal medicine ,Neoplasms ,Medicine ,Humans ,030212 general & internal medicine ,Sex Distribution ,Lung cancer ,education ,Aged ,Cervical cancer ,Aged, 80 and over ,education.field_of_study ,Surveillance Summaries ,Cancer prevention ,business.industry ,Incidence (epidemiology) ,Incidence ,Cancer ,Middle Aged ,medicine.disease ,United States ,030220 oncology & carcinogenesis ,Population Surveillance ,Female ,business - Abstract
Problem/condition Tobacco use is the leading preventable cause of cancer, contributing to at least 12 types of cancer, including acute myeloid leukemia (AML) and cancers of the oral cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, bronchus, and trachea; kidney and renal pelvis; urinary bladder; and cervix. This report provides a comprehensive assessment of recent tobacco-associated cancer incidence for each cancer type by sex, age, race/ethnicity, metropolitan county classification, tumor characteristics, U.S. census region, and state. These data are important for initiation, monitoring, and evaluation of tobacco prevention and control measures. Period covered 2010-2014. Description of system Cancer incidence data from CDC's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology, and End Results program were used to calculate average annual age-adjusted incidence rates for 2010-2014 and trends in annual age-adjusted incidence rates for 2010-2014. These cancer incidence data cover approximately 99% of the U.S. Population This report provides age-adjusted cancer incidence rates for each of the 12 cancer types known to be causally associated with tobacco use, including liver and colorectal cancer, which were deemed to be causally associated with tobacco use by the U.S. Surgeon General in 2014. Findings are reported by demographic and geographic characteristics, percentage distributions for tumor characteristics, and trends in cancer incidence by sex. Results During 2010-2014, approximately 3.3 million new tobacco-associated cancer cases were reported in the United States, approximately 667,000 per year. Age-adjusted incidence rates ranged from 4.2 AML cases per 100,000 persons to 61.3 lung cancer cases per 100,000 persons. By cancer type, incidence rates were higher among men than women (excluding cervical cancer), higher among non-Hispanics than Hispanics (for all cancers except stomach, liver, kidney, and cervical), higher among persons in nonmetropolitan counties than those in metropolitan counties (for all cancers except stomach, liver, pancreatic, and AML), and lower in the West than in other U.S. census regions (all except stomach, liver, bladder, and AML). Compared with other racial/ethnic groups, certain cancer rates were highest among whites (oral cavity and pharyngeal, esophageal, bladder, and AML), blacks (colon and rectal, pancreatic, laryngeal, lung and bronchial, cervical, and kidney), and Asians/Pacific Islanders (stomach and liver). During 2010-2014, the rate of all tobacco-associated cancers combined decreased 1.2% per year, influenced largely by decreases in cancers of the larynx (3.0%), lung (2.2%), colon and rectum (2.1%), and bladder (1.3%). Interpretation Although tobacco-associated cancer incidence decreased overall during 2010-2014, the incidence remains high in several states and subgroups, including among men, whites, blacks, non-Hispanics, and persons in nonmetropolitan counties. These disproportionately high rates of tobacco-related cancer incidence reflect overall demographic patterns of cancer incidence in the United States and also reflect patterns of tobacco use. Public health action Tobacco-associated cancer incidence can be reduced through prevention and control of tobacco use and comprehensive cancer-control efforts focused on reducing cancer risk, detecting cancer early, and better assisting communities disproportionately affected by cancer. Ongoing surveillance to monitor cancer incidence can identify populations with a high incidence of tobacco-associated cancers and evaluate the effectiveness of tobacco control programs and policies. Implementation research can be conducted to achieve wider adoption of existing evidence-based cancer prevention and screening programs and tobacco control measures, especially to reach groups with the largest disparities in cancer rates.
- Published
- 2018
27. Rural Cancer Control: Bridging the Chasm in Geographic Health Inequity
- Author
-
Ahmedin Jemal and S. Jane Henley
- Subjects
education.field_of_study ,Bridging (networking) ,Epidemiology ,Population ,MEDLINE ,Affect (psychology) ,Article ,Health equity ,03 medical and health sciences ,0302 clinical medicine ,Geography ,Oncology ,Cancer control ,030220 oncology & carcinogenesis ,Environmental health ,030212 general & internal medicine ,Rural area ,Cancer risk ,education - Abstract
Studies have shown time after time that where people live can affect what diseases they get, how they die, and when they die ([1–6][1]). In 2017, about 15% of the U.S. population, about 46 million people, lived in rural areas. Although geography alone cannot predict cancer risk, it can impact
- Published
- 2018
28. Incidence and Mortality of Cancers of the Biliary Tract, Gallbladder, and Liver by Sex, Age, Race/Ethnicity, and Stage at Diagnosis: United States, 2013 to 2017
- Author
-
Behnoosh Momin, S. Jane Henley, Manxia Wu, A. Blythe Ryerson, Reda J. Wilson, and Taylor D. Ellington
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Epidemiology ,Population ,Intrahepatic bile ducts ,Gastroenterology ,Article ,Young Adult ,Internal medicine ,medicine ,Humans ,Registries ,education ,Child ,Aged ,Aged, 80 and over ,education.field_of_study ,Bile duct ,business.industry ,Mortality rate ,Incidence (epidemiology) ,Incidence ,Liver Neoplasms ,Ampulla of Vater ,Infant, Newborn ,Infant ,Middle Aged ,United States ,medicine.anatomical_structure ,Oncology ,Bile Duct Neoplasms ,Biliary tract ,Child, Preschool ,Population Surveillance ,Pacific islanders ,Female ,Gallbladder Neoplasms ,business - Abstract
Background: Few population-based studies have examined incidence and mortality of cancers of the biliary tract, including intrahepatic bile duct, extrahepatic bile duct, ampulla of Vater, and overlapping or other lesions of the biliary tract in one study. Methods: To further the understanding of recent rates of biliary tract cancers, we used population-based data, to examine incidence and mortality during 2013 to 2017. We examined how rates varied by sex, age, race/ethnicity, U.S. census region, and stage at diagnosis. Results: Intrahepatic bile duct was the most common biliary tract cancer, with an incidence rate of 1.49 per 100,000 persons. Cancer incidence rates per 100,000 persons were 0.96 for extrahepatic bile duct, 0.45 for ampulla of Vater, and 0.24 for overlapping or other lesions of the biliary tract. Cancer death rates per 100,000 persons were 1.66 for intrahepatic bile duct and 0.45 for other biliary tract. Intrahepatic bile duct incidence and death rates were higher among males than females, higher among Hispanic and Asian and Pacific Islander persons compared with non-Hispanic Whites, and higher in the Northeast and in urban counties. Conclusions: This report provides national estimates of these rare biliary tract cancers. Impact: Key interventions targeted to high-risk populations may help reduce incidence and mortality of cancers of the biliary tract by improving primary prevention through strategies to reduce tobacco and alcohol use, control overweight and obesity, and promote hepatitis B vaccination and use of syringe service programs meant to curb the transmission of infectious diseases such as viral hepatitis.
- Published
- 2021
29. Improving Screening Uptake among Breast Cancer Survivors and Their First-Degree Relatives at Elevated Risk to Breast Cancer: Results and Implications of a Randomized Study in the State of Georgia
- Author
-
Cam Escoffery, Toni Chociemski, Renjian Jiang, Michael Goodman, Kevin C. Ward, Robert A. Smith, S. Jane Henley, Theresa W. Gillespie, Xi Sheng, Lyn Almon, and Joseph Lipscomb
- Subjects
Counseling ,Health, Toxicology and Mutagenesis ,lcsh:Medicine ,community-based research ,first-degree relatives ,law.invention ,Breast cancer screening ,0302 clinical medicine ,Cancer Survivors ,Randomized controlled trial ,Disease Screening ,law ,Surveys and Questionnaires ,Cancer screening ,disease screening ,Mass Screening ,Medicine ,Registries ,030212 general & internal medicine ,10. No inequality ,skin and connective tissue diseases ,guideline adherence ,Early Detection of Cancer ,medicine.diagnostic_test ,Middle Aged ,3. Good health ,030220 oncology & carcinogenesis ,Female ,Adult ,medicine.medical_specialty ,Georgia ,breast cancer survivors ,Breast Neoplasms ,Article ,03 medical and health sciences ,Breast cancer ,Internal medicine ,Humans ,business.industry ,lcsh:R ,Public Health, Environmental and Occupational Health ,Cancer ,Guideline ,medicine.disease ,population-based genetic risk screening ,Telephone ,Cancer registry ,cancer registries ,Patient Compliance ,business - Abstract
Women diagnosed with breast cancer at a relatively early age (&le, 45 years) or with bilateral disease at any age are at elevated risk for additional breast cancer, as are their female first-degree relatives (FDRs). We report on a randomized trial to increase adherence to mammography screening guidelines among survivors and FDRs. From the Georgia Cancer Registry, breast cancer survivors diagnosed during 2000&ndash, 2009 at six Georgia cancer centers underwent phone interviews about their breast cancer screening behaviors and their FDRs. Nonadherent survivors and FDRs meeting all inclusion criteria were randomized to high-intensity (evidence-based brochure, phone counseling, mailed reminders, and communications with primary care providers) or low-intensity interventions (brochure only). Three and 12-month follow-up questionnaires were completed. Data analyses used standard statistical approaches. Among 1055 survivors and 287 FDRs who were located, contacted, and agreed to participate, 59.5% and 62.7%, respectively, reported breast cancer screening in the past 12 months and were thus ineligible. For survivors enrolled at baseline (N = 95), the proportion reporting adherence to guideline screening by 12 months post-enrollment was similar in the high and low-intensity arms (66.7% vs. 79.2%, p = 0.31). Among FDRs enrolled at baseline (N = 83), screening was significantly higher in the high-intensity arm at 12 months (60.9% vs. 32.4%, p = 0.03). Overall, about 72% of study-eligible survivors (all of whom were screening nonadherent at baseline) reported screening within 12 months of study enrollment. For enrolled FDRs receiving the high-intensity intervention, over 60% reported guideline screening by 12 months. A major conclusion is that using high-quality central cancer registries to identify high-risk breast cancer survivors and then working closely with these survivors to identify their FDRs represents a feasible and effective strategy to promote guideline cancer screening.
- Published
- 2020
30. Pediatric cancer mortality and survival in the United States, 2001-2016
- Author
-
Eric Tai, David A. Siegel, S. Jane Henley, Natasha Buchanan Lunsford, Reda J. Wilson, Hannah K. Weir, Lisa C. Richardson, and Nicole F. Dowling
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,History, 21st Century ,Article ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Neoplasms ,Epidemiology ,medicine ,Humans ,030212 general & internal medicine ,Socioeconomic status ,Relative survival ,business.industry ,Mortality rate ,Cancer ,medicine.disease ,Pediatric cancer ,Survival Analysis ,United States ,Lymphoma ,Leukemia ,Oncology ,030220 oncology & carcinogenesis ,business ,Demography - Abstract
Background Although pediatric cancer mortality and survival have improved in the United States over the past 40 years, differences exist by age, race/ethnicity, cancer site, and economic status. To assess progress, this study examined recent mortality and survival data for individuals younger than 20 years. Methods Age-adjusted death rates were calculated with the National Vital Statistics System for 2002-2016. Annual percent changes (APCs) and average annual percent changes (AAPCs) were calculated with joinpoint regression. Five-year relative survival was calculated on the basis of National Program of Cancer Registries data for 2001-2015. Death rates and survival were estimated overall and by sex, 5-year age group, race/ethnicity, cancer type, and county-based economic markers. Results Death rates decreased during 2002-2016 (AAPC, -1.5), with steeper declines during 2002-2009 (APC, -2.6), and then plateaued (APC, -0.4). Leukemia and brain cancer were the most common causes of death from pediatric cancer, and brain cancer surpassed leukemia in 2011. Death rates decreased for leukemia and lymphoma but were unchanged for brain, bone, and soft-tissue cancers. From 2001-2007 to 2008-2015, survival improved from 82.0% to 85.1%. Survival was highest in both periods among females, those aged 15 to 19 years, non-Hispanic Whites, and those in counties in the top 25% by economic status. Survival improved for leukemias, lymphomas, and brain cancers but plateaued for bone and soft-tissue cancers. Conclusions Although overall death rates have decreased and survival has increased, differences persist by sex, age, race/ethnicity, cancer type, and economic status. Improvements in pediatric cancer outcomes may depend on improving therapies, access to care, and supportive and long-term care.
- Published
- 2019
31. Geographic Variation in Pediatric Cancer Incidence — United States, 2003–2014
- Author
-
S. Jane Henley, David A. Siegel, Natasha Buchanan Lunsford, Eric Tai, Elizabeth A. Van Dyne, Jun Li, and Reda J. Wilson
- Subjects
Male ,medicine.medical_specialty ,Health (social science) ,Census Region ,Adolescent ,Epidemiology ,Health, Toxicology and Mutagenesis ,Psychological intervention ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Health Information Management ,030225 pediatrics ,Neoplasms ,Medicine ,Humans ,Full Report ,Registries ,Young adult ,Child ,business.industry ,Incidence (epidemiology) ,Public health ,Incidence ,Infant, Newborn ,Cancer ,Infant ,General Medicine ,medicine.disease ,Pediatric cancer ,United States ,Clinical trial ,030220 oncology & carcinogenesis ,Child, Preschool ,Population Surveillance ,Female ,business ,Demography - Abstract
Approximately 15,000 persons aged
- Published
- 2018
32. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
- Author
-
Ahmedin Jemal, Jiemin Ma, Robert N. Anderson, Andrew J. Lake, Recinda L. Sherman, Nadia Howlader, Albert U. Firth, Anne-Michelle Noone, Susan Scott, Kathleen A. Cronin, S. Jane Henley, and Betsy A. Kohler
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Mortality rate ,Incidence (epidemiology) ,Population ,Cancer ,medicine.disease ,Cancer registry ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Epidemiology ,medicine ,Young adult ,education ,business ,Demography ,Cause of death - Abstract
Background The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Methods Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention-funded and National Cancer Institute-funded population-based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012-2016 for incidence and 2013-2017 for mortality). Results Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non-Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017. Conclusions Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population-based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals.
- Published
- 2018
33. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics
- Author
-
Angela B. Mariotto, Barbara J. Dearmon, Recinda L. Sherman, Lynne Penberthy, Eric J. Feuer, Ahmedin Jemal, Stacey A. Fedewa, Andrew J. Lake, Serban Negoita, Kathleen A. Cronin, Vicki B. Benard, S. Jane Henley, Lisa C. Richardson, Robert N. Anderson, Valentina I. Petkov, Jiemin Ma, Sarah Hussey, and Betsy A. Kohler
- Subjects
Cancer Research ,education.field_of_study ,business.industry ,Mortality rate ,Incidence (epidemiology) ,Population ,Cancer ,Disease ,medicine.disease ,Annual Percent Change ,03 medical and health sciences ,Prostate-specific antigen ,Prostate cancer ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Medicine ,030212 general & internal medicine ,business ,education ,Demography - Abstract
Background Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national-level trends and their relations with prostate-specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage-specific, delay-adjusted rates. Methods Joinpoint regression was used to examine changes in delay-adjusted prostate cancer incidence rates from population-based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points. Results For all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant-stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015. Conclusions After a decline in PSA test usage, there has been an increased burden of late-stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801-2814. © 2018 American Cancer Society.
- Published
- 2018
34. Cost of Tobacco-related Cancer Hospitalizations in the U.S., 2014
- Author
-
S. Jane Henley, Eric Tai, C. Brooke Steele, Michael Shayne Gallaway, Gery P. Guy, and Lisa C. Richardson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Epidemiology ,Rectum ,Oral cavity ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cost of Illness ,Neoplasms ,Internal medicine ,Prevalence ,Tobacco Smoking ,medicine ,Humans ,030212 general & internal medicine ,Hospital Costs ,Young adult ,Esophagus ,Cervix ,Aged ,Inpatient care ,business.industry ,Public Health, Environmental and Occupational Health ,Cancer ,Middle Aged ,medicine.disease ,United States ,Hospitalization ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,business ,Medical costs - Abstract
Introduction Smoking has been causally linked to 12 tobacco-related cancers: oral cavity and pharynx, esophagus, stomach, colon and rectum, liver, pancreas, larynx, lung, cervix, bladder, kidney, and acute myeloid leukemia. Tobacco-related cancers−related morbidity and mortality have been well described, but little is known about the prevalence of tobacco-related cancer hospitalizations and associated costs. This study estimates the annual number of tobacco-related cancer hospitalizations and their associated direct medical costs in the U.S. Methods This study examined data from the 2014 National Inpatient Sample, the largest publicly available all-payer inpatient care database in the U.S. The authors calculated number of hospitalizations, total costs, length of stay, and cost per stay for tobacco-related cancer hospitalizations and cancer hospitalizations not related to tobacco. Results In 2014, there were an estimated 461,295 annual tobacco-related cancer hospitalizations at a cost of $8.2 billion in the U.S. Tobacco-related cancers accounted for 45% of total cancer hospitalizations and cancer hospitalization costs. Compared with cancer hospitalizations not related to tobacco, tobacco-related cancer hospitalizations had a longer mean length of stay (6.8 vs 5.7 days). Conclusions The burden of tobacco-related cancer hospitalizations is substantial in the U.S. These findings highlight the importance of tobacco prevention and cessation efforts to decrease the burden of tobacco-related cancers in the U.S.
- Published
- 2018
35. Capture of tobacco use among population-based registries: Findings from 10 National Program of Cancer Registries states
- Author
-
Judy R. Rees, Jennifer M. Wike, David A. Siegel, Lori A. Pollack, A. Blythe Ryerson, Christopher J. Johnson, and S. Jane Henley
- Subjects
Cancer Research ,medicine.medical_specialty ,Tobacco use ,business.industry ,Medical record ,Cancer ,Population based ,medicine.disease ,Primary cancer ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Smokeless tobacco ,030220 oncology & carcinogenesis ,Epidemiology ,medicine ,030212 general & internal medicine ,Bronchus cancer ,business ,Demography - Abstract
Background Tobacco use data are important when the epidemiology and prognosis of tobacco-associated cancers are being defined. Central cancer registries in 10 National Program of Cancer Registries states pilot-tested the collection of standardized tobacco use variables. This study evaluated the capture of tobacco use data and examined smoking prevalence among cancer patients. Methods Participating registries collected data about the use of tobacco-cigarettes, other smoked tobacco, and smokeless tobacco-for cases diagnosed during 2011-2013. The percentage of cases with known tobacco variable values was calculated, and the prevalence of tobacco use was analyzed by the primary cancer site and state. Results Among 1,646,505 incident cancer cases, 51% had known cigarette use data: 18% were current users, 31% were former users, and 51% reported never using. The percentage of cases with a known status for both other smoked tobacco and smokeless tobacco was 43%, with 97% and 98% coded as never users, respectively. The percent known for cigarette use ranged from 27% to 81% by state and improved from 47% in 2011 to 59% in 2013 for all 10 states combined. The percent known for cigarette use and the prevalence of ever smoking cigarettes were highest for laryngeal cancer and tracheal, lung, and bronchus cancer. Conclusions Cancer registrars ascertained cigarette use for slightly more than half of all new cancer cases, but other tobacco-related fields were less complete. Studies to evaluate the validity of specific tobacco-related variables and the ability of cancer registries to capture this information from the medical record are needed to gauge the usefulness of collecting these variables through cancer surveillance systems. Cancer 2018;124:2381-9. © 2018 American Cancer Society.
- Published
- 2018
36. Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study
- Author
-
Hannah K. Weir, Claudia Allemani, Bin Huang, Thomas B. Richards, S. Jane Henley, Mary Puckett, and Thomas C. Tucker
- Subjects
Cancer Research ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Cancer ,medicine.disease ,Confidence interval ,03 medical and health sciences ,Race (biology) ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Epidemiology ,medicine ,030212 general & internal medicine ,Stage (cooking) ,Young adult ,business ,education ,Lung cancer ,Demography - Abstract
Background Results from the second CONCORD study (CONCORD-2) indicated that 5-year net survival for lung cancer was low (range, 10%-20%) between 1995 and 2009 in most countries, including the United States, which was at the higher end of this range. Methods Data from CONCORD-2 were used to analyze net survival among patients with lung cancer (aged 15-99 years) who were diagnosed in 37 states covering 80% of the US population. Survival was corrected for background mortality using state-specific and race-specific life tables and age-standardized using International Cancer Survival Standard weights. Net survival was estimated for patients diagnosed between 2001 and 2003 and between 2004 and 2009 at 1, 3, and 5 years after diagnosis by race (all races, black, and white); Surveillance, Epidemiology, and End Results Summary Stage 2000; and US state. Results Five-year net survival increased from 16.4% (95% confidence interval, 16.3%-16.5%) for patients diagnosed 2001-2003 to 19.0% (18.8%-19.1%) for those diagnosed 2004-2009, with increases in most states and among both blacks and whites. Between 2004 and 2009, 5-year survival was lower among blacks (14.9%) than among whites (19.4%) and ranged by state from 14.5% to 25.2%. Conclusions Lung cancer survival improved slightly between the periods 2001-2003 and 2004-2009 but was still low, with variation between states, and persistently lower survival among blacks than whites. Efforts to control well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients receive timely and appropriate treatment should reduce the differences in survival by race and state. Cancer 2017;123:5079-99. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
- Published
- 2017
37. Five-year relative survival for human papillomavirus-associated cancer sites
- Author
-
Trevor D. Thompson, Mona Saraiya, Reda J. Wilson, Hilda Razzaghi, S. Jane Henley, and Laura Viens
- Subjects
Oncology ,Cervical cancer ,Cancer Research ,medicine.medical_specialty ,Vaginal cancer ,education.field_of_study ,Relative survival ,business.industry ,Population ,Vulvar cancer ,medicine.disease ,stomatognathic diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Anal cancer ,Penile cancer ,030212 general & internal medicine ,education ,business ,Survival rate - Abstract
BACKGROUND Human papillomavirus (HPV) vaccines can potentially prevent greater than 90% of cervical and anal cancers as well as a substantial proportion of vulvar, vaginal, penile, and oropharyngeal cancers caused by certain HPV types. Because more than 38,000 HPV-associated cancers are diagnosed annually in the United States, current studies are needed to understand how relative survival varies for each of these cancers by certain demographic characteristics, such as race and age. METHODS The authors examined high-quality data from 27 population-based cancer registries covering approximately 59% of the US population. The analyses were limited to invasive cancers that were diagnosed during 2001 through 2011 and followed through 2011 and met specified histologic criteria for HPV-associated cancers. Five-year relative survival was calculated from diagnosis until death for these cancers by age, race, and sex. RESULTS The 5-year age-standardized relative survival rate was 64.2% for cervical carcinomas, 52.8% for vaginal squamous cell carcinomas (SCCs), 66% for vulvar SCCs, 47.4% for penile SCCs, 65.9% for anal SCCs, 56.2% for rectal SCCs, and 51.2% for oropharyngeal SCCs. Five-year relative survival was consistently higher among white patients compared with black patients for all HPV-associated cancers across all age groups; the greatest differences by race were observed for oropharyngeal SCCs among those aged
- Published
- 2017
38. Alcohol Screening and Brief Intervention: A Potential Role in Cancer Prevention for Young Adults
- Author
-
Erika Odom, Daniel W. Hungerford, Patricia P. Green, S. Jane Henley, and Lela R. McKnight-Eily
- Subjects
Adult ,Counseling ,Male ,medicine.medical_specialty ,Alcohol Drinking ,Epidemiology ,Binge drinking ,Context (language use) ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Neoplasms ,Intervention (counseling) ,Preventive Health Services ,Health care ,Prevalence ,medicine ,Humans ,Mass Screening ,030212 general & internal medicine ,Young adult ,Psychiatry ,Mass screening ,Aged ,Cancer prevention ,Ethanol ,Primary Health Care ,business.industry ,Age Factors ,Public Health, Environmental and Occupational Health ,Middle Aged ,United States ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Female ,Centers for Disease Control and Prevention, U.S ,Brief intervention ,business ,Alcohol-Related Disorders - Abstract
Excessive or risky alcohol use is a preventable cause of significant morbidity and mortality in the U.S. and worldwide. Alcohol use is a common preventable cancer risk factor among young adults; it is associated with increased risk of developing at least six types of cancer. Alcohol consumed during early adulthood may pose a higher risk of female breast cancer than alcohol consumed later in life. Reducing alcohol use may help prevent cancer. Alcohol misuse screening and brief counseling or intervention (also called alcohol screening and brief intervention among other designations) is known to reduce excessive alcohol use, and the U.S. Preventive Services Task Force recommends that it be implemented for all adults aged ≥ 18 years in primary healthcare settings. Because the prevalence of excessive alcohol use, particularly binge drinking, peaks among young adults, this time of life may present a unique window of opportunity to talk about the cancer risk associated with alcohol use and how to reduce that risk by reducing excessive drinking or misuse. This article briefly describes alcohol screening and brief intervention, including the Centers for Disease Control and Prevention’s recommended approach, and suggests a role for it in the context of cancer prevention. The article also briefly discusses how the Centers for Disease Control and Prevention is working to make alcohol screening and brief intervention a routine element of health care in all primary care settings to identify and help young adults who drink too much.
- Published
- 2017
39. Invasive Cancer Incidence, 2004–2013, and Deaths, 2006–2015, in Nonmetropolitan and Metropolitan Counties — United States
- Author
-
S. Jane Henley, Cheryll C. Thomas, Lisa C. Richardson, Brandy Peaker, Greta M. Massetti, and Robert N Anderson
- Subjects
Adult ,Male ,Rural Population ,Health (social science) ,Urban Population ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,01 natural sciences ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Health Information Management ,Risk Factors ,Neoplasms ,Cancer screening ,medicine ,Ethnicity ,Humans ,Neoplasm Invasiveness ,030212 general & internal medicine ,Registries ,0101 mathematics ,education ,Aged ,education.field_of_study ,Surveillance Summaries ,Cancer prevention ,Incidence (epidemiology) ,Mortality rate ,Incidence ,010102 general mathematics ,Racial Groups ,Cancer ,Health Status Disparities ,Middle Aged ,medicine.disease ,Metropolitan area ,United States ,Geography ,Population Surveillance ,Female ,Rural area ,Centers for Disease Control and Prevention, U.S ,Demography - Abstract
PROBLEM/CONDITION Previous reports have shown that persons living in nonmetropolitan (rural or urban) areas in the United States have higher death rates from all cancers combined than persons living in metropolitan areas. Disparities might vary by cancer type and between occurrence and death from the disease. This report provides a comprehensive assessment of cancer incidence and deaths by cancer type in nonmetropolitan and metropolitan counties. REPORTING PERIOD 2004-2015. DESCRIPTION OF SYSTEM Cancer incidence data from CDC's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology, and End Results program were used to calculate average annual age-adjusted incidence rates for 2009-2013 and trends in annual age-adjusted incidence rates for 2004-2013. Cancer mortality data from the National Vital Statistics System were used to calculate average annual age-adjusted death rates for 2011-2015 and trends in annual age-adjusted death rates for 2006-2015. For 5-year average annual rates, counties were classified into four categories (nonmetropolitan rural, nonmetropolitan urban, metropolitan with population
- Published
- 2017
40. Surveillance for Cancer Incidence and Mortality — United States, 2013
- Author
-
S. Jane Henley, A. Blythe Ryerson, and Simple D. Singh
- Subjects
Adult ,Male ,0301 basic medicine ,Gerontology ,medicine.medical_specialty ,Health (social science) ,Adolescent ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,MEDLINE ,Death Certificates ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Neoplasms ,Ethnicity ,Humans ,Medicine ,Registries ,Young adult ,education ,Aged ,Surveillance Summaries ,education.field_of_study ,business.industry ,Incidence ,Incidence (epidemiology) ,Racial Groups ,Cancer ,Middle Aged ,medicine.disease ,National Cancer Institute (U.S.) ,United States ,Vital Statistics ,030104 developmental biology ,Cancer incidence ,Population Surveillance ,030220 oncology & carcinogenesis ,Family medicine ,Female ,Death certificate ,Centers for Disease Control and Prevention, U.S ,business ,SEER Program - Abstract
This report provides, in tabular and graphic form, official federal statistics on cancer incidence and mortality for 2013 and trends for 1999-2013 as reported by CDC and the National Cancer Institute (NCI). Data in this report come from the United States Cancer Statistics (USCS) system (1), which includes cancer incidence data from population-based cancer registries that participate in CDC's National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology, and End Results (SEER) program reported as of November 2015 and cancer mortality data from death certificate information reported to state vital statistics offices as of June 2015 and compiled into a national file for the entire United States by CDC's National Center for Health Statistics (NCHS) National Vital Statistics System (NVSS).
- Published
- 2017
41. Invasive Cancer Incidence and Survival — United States, 2013
- Author
-
Reda J. Wilson, A. Blythe Ryerson, Simple D. Singh, Mary Elizabeth O'Neil, S. Jane Henley, and Jessica B. King
- Subjects
Adult ,Male ,medicine.medical_specialty ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Ethnic group ,White People ,Young Adult ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Health Information Management ,Risk Factors ,Neoplasms ,Ethnicity ,medicine ,Humans ,Neoplasm Invasiveness ,Registries ,Full Report ,030212 general & internal medicine ,Sex Distribution ,Young adult ,Survival rate ,Aged ,Invasive carcinoma ,business.industry ,Incidence ,Incidence (epidemiology) ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,United States ,Black or African American ,Survival Rate ,Cancer incidence ,Population Surveillance ,030220 oncology & carcinogenesis ,Female ,Outcomes research ,business ,SEER Program ,Demography - Abstract
Although cancer represents many heterogeneous diseases, some cancer types share common risk factors. For example, conclusive evidence links cancer at multiple sites with tobacco use, alcohol use, human papillomavirus (HPV) infection, excess body weight, and physical inactivity (1,2). To monitor changes in cancer incidence and assess progress toward achieving Healthy People 2020 objectives,* CDC analyzed data from the U.S. Cancer Statistics (USCS) data set for 2013, the most recent year for which incidence and survival data are available. In 2013, a total of 1,559,130 invasive cancers were reported to cancer registries in the United States (excluding Nevada), for an annual age-adjusted incidence rate of 439 cases per 100,000 persons. Cancer incidence rates were higher among males (479) than females (413), highest among blacks (444), and ranged by state from 364 (New Mexico) to 512 (Kentucky) per 100,000 persons (359 in Puerto Rico). The proportion of persons with cancer who survived ≥5 years after diagnosis was 67%. This proportion was the same for males and females (67%), but lower among blacks (62%) than among whites (67%). Cancer surveillance data are key to cancer epidemiologic and clinical outcomes research, program planning and monitoring, resource allocation, and state and federal appropriations accountability.
- Published
- 2017
42. Vital Signs: Disparities in Tobacco-Related Cancer Incidence and Mortality — United States, 2004–2013
- Author
-
Behnoosh Momin, Cheryll C. Thomas, Deborah M Winn, Saida R. Sharapova, S. Jane Henley, Brian S. Armour, Greta M. Massetti, and Lisa C. Richardson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Health (social science) ,Epidemiology ,Health, Toxicology and Mutagenesis ,Vital signs ,Rectum ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Health Information Management ,Quality of life ,Neoplasms ,Environmental health ,Ethnicity ,medicine ,Humans ,030212 general & internal medicine ,Sex Distribution ,Cervix ,Aged ,business.industry ,Incidence ,Mortality rate ,Incidence (epidemiology) ,Public health ,Racial Groups ,Smoking ,Cancer ,Health Status Disparities ,General Medicine ,Middle Aged ,medicine.disease ,United States ,medicine.anatomical_structure ,Socioeconomic Factors ,030220 oncology & carcinogenesis ,Female ,business ,Demography - Abstract
Background Tobacco use causes at least 12 types of cancer and is the leading preventable cause of cancer. Methods Data from the United States Cancer Statistics dataset for 2004-2013 were used to assess incidence and death rates and trends for cancers that can be caused by tobacco use (tobacco-related cancers: oral cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, bronchus, and trachea; kidney and renal pelvis; urinary bladder; cervix; and acute myeloid leukemia) by sex, age, race, ethnicity, state, county-level poverty and educational attainment, and cancer site. Results Each year during 2009-2013, on average, 660,000 persons in the United States received a diagnosis of a tobacco-related cancer, and 343,000 persons died from these cancers. Tobacco-related cancer incidence and death rates were higher among men than women; highest among black men and women; higher in counties with low proportion of college graduates or high level of poverty; lowest in the West; and differed two-fold among states. During 2004-2013, incidence of tobacco-related cancer decreased 1.3% per year and mortality decreased 1.6% per year, with decreases observed across most groups, but not at the same rate. Conclusions Tobacco-related cancer declined during 2004-2013. However, the burden remains high, and disparities persist among certain groups with higher rates or slower declines in rates. Implications for public health practice The burden of tobacco-related cancers can be reduced through efforts to prevent and control tobacco use and other comprehensive cancer control efforts focused on reducing cancer risk, detecting cancer early, improving cancer treatments, helping more persons survive cancer, improving cancer survivors' quality of life, and better assisting communities disproportionately impacted by cancer.
- Published
- 2016
43. Multilevel Small-Area Estimation of Multiple Cigarette Smoking Status Categories Using the 2012 Behavioral Risk Factor Surveillance System
- Author
-
James B. Holt, Zahava Berkowitz, Thomas B. Richards, S. Jane Henley, Xingyou Zhang, and Lucy A. Peipins
- Subjects
Adult ,Male ,Adolescent ,Epidemiology ,Population ,Article ,Cigarette Smoking ,Behavioral Risk Factor Surveillance System ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Small area estimation ,Risk Factors ,Environmental health ,Health care ,Prevalence ,Humans ,Medicine ,National Health Interview Survey ,030212 general & internal medicine ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,030505 public health ,business.industry ,Tobacco control ,Middle Aged ,Former Smoker ,United States ,Oncology ,Sample size determination ,Female ,0305 other medical science ,business - Abstract
Background: Smoking is the leading preventable cause of death; however, small-area estimates for detailed smoking status are limited. We developed multilevel small-area estimate mixed models to generate county-level estimates for six smoking status categories: current, some days, every day, former, ever, and never. Method: Using 2012 Behavioral Risk Factor Surveillance System (BRFSS) data (our sample size = 405,233 persons), we constructed and fitted a series of multilevel logistic regression models and applied them to the U.S. Census population to generate county-level prevalence estimates. We mapped the estimates by sex and aggregated them into state and national estimates. We conducted comparisons for internal consistency with BRFSS states' estimates using Pearson correlation coefficients, and external validation with the 2012 National Health Interview Survey current smoking prevalence. Results: Correlation coefficients ranged from 0.908 to 0.982, indicating high internal consistency. External validation indicated complete agreement (prevalence = 18.06%). We found large variations in current and former smoking status between and within states and by sex. County prevalence of former smokers was highest among men in the Northeast, North, and West. Utah consistently had the lowest smoking prevalence. Conclusions: Our models, which include demographic and geographic characteristics, provide reliable estimates that can be applied to multiple category outcomes and any demographic group. County and state estimates may help understand the variation in smoking prevalence in the United States and provide information for control and prevention. Impact: Detailed county and state smoking category estimates can help identify areas in need of tobacco control and prevention and potentially allow planning for health care. Cancer Epidemiol Biomarkers Prev; 25(10); 1402–10. ©2016 AACR.
- Published
- 2016
44. Human Papillomavirus-Attributable Cancers - United States, 2012-2016
- Author
-
Cheryll C. Thomas, Lauri E. Markowitz, Mona Saraiya, Virginia Senkomago, S. Jane Henley, and Jacqueline M. Mix
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Health (social science) ,Vaginal Neoplasms ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,Uterine Cervical Neoplasms ,Genital warts ,Vulva ,03 medical and health sciences ,Papillomavirus Vaccines ,0302 clinical medicine ,Health Information Management ,030225 pediatrics ,Internal medicine ,Neoplasms ,Cancer screening ,medicine ,Humans ,030212 general & internal medicine ,Registries ,Full Report ,education ,Penile Neoplasms ,education.field_of_study ,Vulvar Neoplasms ,business.industry ,Incidence (epidemiology) ,Incidence ,Papillomavirus Infections ,virus diseases ,Cancer ,General Medicine ,medicine.disease ,Anus Neoplasms ,United States ,Oropharyngeal Neoplasms ,medicine.anatomical_structure ,Oropharyngeal Neoplasm ,Population Surveillance ,Female ,business - Abstract
Human papillomavirus (HPV) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and oropharynx (1).* Most HPV infections are asymptomatic and clear spontaneously within 1 to 2 years; however, persistent infection with oncogenic HPV types can lead to development of precancer or cancer (2). In the United States, the 9-valent HPV vaccine (9vHPV) is available to protect against oncogenic HPV types 16, 18, 31, 33, 45, 52, and 58 as well as nononcogenic types 6 and 11 that cause genital warts. CDC analyzed data from the U.S. Cancer Statistics (USCS)† to assess the incidence of HPV-associated cancers and to estimate the annual number of cancers caused by HPV, overall and by state, during 2012-2016 (3,4). An average of 43,999 HPV-associated cancers were reported annually, and an estimated 34,800 (79%) of those cancers were attributable to HPV. Of these 34,800 cancers, an estimated 32,100 (92%) were attributable to the types targeted by 9vHPV, with 19,000 occurring among females and 13,100 among males. The most common were cervical (9,700) and oropharyngeal cancers (12,600). The number of cancers estimated to be attributable to the types targeted by 9vHPV ranged by state from 40 to 3,270 per year. HPV vaccination is an important strategy that could prevent these cancers, but during 2018, only half of adolescents were up to date on HPV vaccination (5). These surveillance data from population-based cancer registries can be used to inform the planning for, and monitor the long-term impact of, HPV vaccination and cancer screening efforts nationally and within states.
- Published
- 2019
45. Smoking cessation behaviors among older U.S. adults
- Author
-
M. Shayne Gallaway, Stephen Babb, Kat Asman, S. Jane Henley, Thomas B. Richards, Behnoosh Momin, MaryBeth B. Culp, and Kathleen R. Ragan
- Subjects
Gerontology ,medicine.medical_treatment ,Population ,Psychological intervention ,030209 endocrinology & metabolism ,Health Informatics ,Smoking cessation ,Quit smoking ,03 medical and health sciences ,0302 clinical medicine ,Cigarette smoking ,medicine ,National Health Interview Survey ,030212 general & internal medicine ,Tobacco price ,education ,Tobacco cessation treatment ,education.field_of_study ,Cancer prevention ,business.industry ,Public Health, Environmental and Occupational Health ,Regular Article ,Older adults ,business - Abstract
Smoking cessation is a critical component of cancer prevention among older adults (age ≥ 65 years). Understanding smoking cessation behaviors among older adults can inform clinical and community efforts to increase successful cessation. We provide current, national prevalence estimates for smoking cessation behaviors among older adults, including interest in quitting, quitting attempts, quitting successes, receiving advice to quit from a healthcare provider, and use of evidence-based tobacco cessation treatments. The 2015 National Health Interview Survey and Cancer Control Supplement were used to estimate cigarette smoking status and cessation behaviors among older US adults across selected socio-demographic and health characteristics. We found that four in five older adults who had ever smoked cigarettes had quit and more than half who currently smoked were interested in quitting but fewer than half made a past-year quit attempt. Two-thirds of older adults said that a healthcare provider advised them to quit smoking, but just over one-third who tried to quit used evidence-based tobacco cessation treatments and only one in 20 successfully quit in the past year. Prevalence estimates for smoking cessation behaviors were similar across most characteristics. Our study demonstrates that few older adults, across most levels of characteristics examined, successfully quit smoking, underscoring the importance of assisting smoking cessation efforts. Healthcare providers can help older adults quit smoking by offering or referring evidence-based cessation treatments. States and communities can implement population-based interventions including tobacco price increases, comprehensive smoke-free policies, high-impact tobacco education media campaigns, and barrier-free access to evidence-based tobacco cessation counseling and medications., Highlights • Smoking cessation among older adults (age ≥ 65 years) is key to cancer prevention. • More than half of older adults who currently smoked were interested in quitting. • Only one in 20 older adults successfully quit smoking in the past year. • Only a third of older adults who tried to quit used a proven cessation treatment. • Clinical and community efforts can boost successful cessation among older adults.
- Published
- 2019
46. Geographic co-occurrence of mesothelioma and ovarian cancer incidence
- Author
-
Jacqueline W. Miller, Sun Hee Rim, Lucy A. Peipins, S. Jane Henley, and Theodore C. Larson
- Subjects
Oncology ,Adult ,Male ,Mesothelioma ,medicine.medical_specialty ,Lung Neoplasms ,macromolecular substances ,Carcinoma, Ovarian Epithelial ,medicine.disease_cause ,Asbestos ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Occupational Exposure ,Epidemiology ,medicine ,Humans ,030212 general & internal medicine ,Registries ,neoplasms ,Aged ,Aged, 80 and over ,Ovarian Neoplasms ,business.industry ,Incidence (epidemiology) ,Incidence ,Cancer ,General Medicine ,respiratory system ,Middle Aged ,medicine.disease ,United States ,respiratory tract diseases ,030220 oncology & carcinogenesis ,Female ,Ovarian cancer ,business - Abstract
BACKGROUND: Asbestos is an established cause of several cancers, including mesothelioma and ovarian cancer. Incidence of mesothelioma, the sentinel asbestos-associated cancer, varies by state, likely reflecting different levels of asbestos exposure. We hypothesized that states with high mesothelioma incidence may also have high ovarian cancer incidence. MATERIALS AND METHODS: Using data from the Centers for Disease Control and Prevention National Program for Cancer Registries and the National Cancer Institute Surveillance, Epidemiology and End Results program, we examined the geographic co-occurrence of mesothelioma and ovarian cancer incidence rates by U.S. state for 2003–2015. RESULTS: By state, mesothelioma incidence ranged from 0.5 to 1.3 cases per 100,000 persons and ovarian cancer incidence ranged from 9 to 12 cases per 100,000 females. When states were grouped by quartile of mesothelioma incidence, the average ovarian cancer incidence rate was 10% higher in states with the highest mesothelioma incidence than in states with the lowest mesothelioma incidence. Ovarian cancer incidence tended to be higher in states with high mesothelioma incidence (Pearson correlation r =0.54; P
- Published
- 2019
47. Utility of Using Cancer Registry Data to Identify Patients for Tobacco Treatment Trials
- Author
-
Krebs, P., Rogers, E., Greenspan, A., Goldfeld, K., Lei, L., Ostroff, J. S., Garrett, B. E., Momin, B., and S Jane Henley
- Subjects
Clinical Trials as Topic ,Neoplasms ,Tobacco ,Electronic Health Records ,Humans ,Registries ,Tobacco Use Disorder ,Article ,Hospitals - Abstract
BACKGROUND: Many tobacco dependent cancer survivors continue to smoke after diagnosis and treatment. This study investigated the extent to which hospital-based cancer registries could be used to identify smokers in order to offer them assistance in quitting. The concordance of tobacco use coded in the registry was compared with tobacco use as coded in the accompanying Electronic Health Records (EHRs). METHODS: We gathered data from three hospital-based cancer registries in New York City during June 2014 to December 2016. For each patient identified as a current combustible tobacco user in the cancer registries, we abstracted tobacco use data from their EHR to independently code and corroborate smoking status. We calculated the proportion of current smokers, former smokers, and never smokers as indicated in the EHR for the hospitals, cancer site, cancer stage, and sex. We used a logistic regression model to estimate the log odds of the registry-based smoking status correctly predicting the EHR-based smoking status. RESULTS: Agreement in current smoking status between the registry-based smoking status and the EHR-based smoking status was 65%, 71%, and 90% at the three participating hospitals. Logistic regression results indicated that agreement in smoking status between the registry and the EHRs varied by hospital, cancer type, and stage, but not by age and sex. CONCLUSIONS: The utility of using tobacco use data in cancer registries for population-based tobacco treatment interventions is dependent on multiple factors including accurate entry into EHR systems, updated data, and consistent smoking status definitions and registry coding protocols. Our study found that accuracy varied across the three hospitals and may not be able to inform interventions at these hospitals at this time. Several changes may be needed to improve the coding of tobacco use status in EHRs and registries.
- Published
- 2019
48. Lung Cancer Among Women in the United States
- Author
-
Behnoosh Momin, Simple D. Singh, Natasha Buchanan Lunsford, Thomas B. Richards, S. Jane Henley, M. Shayne Gallaway, and Mary Elizabeth O'Neil
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Smoking Prevention ,Health Promotion ,Article ,03 medical and health sciences ,0302 clinical medicine ,Age Distribution ,Internal medicine ,Epidemiology ,medicine ,Prevalence ,Humans ,030212 general & internal medicine ,Mortality ,Lung cancer ,Early Detection of Cancer ,Cancer prevention ,Relative survival ,business.industry ,Incidence (epidemiology) ,Incidence ,Cancer ,General Medicine ,respiratory system ,medicine.disease ,Survival Analysis ,United States ,030220 oncology & carcinogenesis ,Smoking cessation ,Women's Health ,Female ,Centers for Disease Control and Prevention, U.S ,business ,Lung cancer screening ,SEER Program - Abstract
November marks Lung Cancer Awareness Month and reminds us that lung cancer is the leading cause of cancer death among women, in the United States. In this brief report we highlight CDC resources that can be used to examine the most recent data about lung cancer incidence, survival, prevalence, and mortality among women. Using the U.S. Cancer Statistics Data Visualizations tool, we report that in 2015, 104,992 new cases of lung cancer and 70,073 lung cancer deaths were reported among women in the United States. The 5-year relative survival among females diagnosed with lung cancer was 22%, and as of 2015, about 185,759 women were living with a lung cancer diagnosis. We also describe ways CDC works to collect and disseminate quality cancer surveillance data, prevent initiation of tobacco use, promote cessation, eliminate exposure to secondhand smoke, identify and eliminate disparities, promote lung cancer screening, and help cancer survivors live longer by improving health outcomes.
- Published
- 2018
49. Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States
- Author
-
David A. Siegel, Lori A. Pollack, Stacey A. Fedewa, Ahmedin Jemal, and S. Jane Henley
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Smokers ,business.industry ,Smoking ,MEDLINE ,respiratory system ,medicine.disease ,Never smokers ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Cigarette smoking ,Risk Factors ,030220 oncology & carcinogenesis ,Internal medicine ,Research Letter ,medicine ,Humans ,Female ,030212 general & internal medicine ,Lung cancer ,business - Abstract
This cross-sectional study examines cigarette smoking patterns by demographic and clinical characteristics among patients with lung cancer.
- Published
- 2021
50. Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015
- Author
-
Cheryll C. Thomas, Elizabeth A. Van Dyne, S. Jane Henley, Lauri E. Markowitz, Mona Saraiya, and Vicki B. Benard
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Health (social science) ,Adolescent ,Epidemiology ,Health, Toxicology and Mutagenesis ,Population ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Age Distribution ,Health Information Management ,Internal medicine ,Neoplasms ,medicine ,Anal cancer ,Penile cancer ,Humans ,030212 general & internal medicine ,Full Report ,Sex Distribution ,education ,Cervix ,Aged ,Cervical cancer ,Vaginal cancer ,education.field_of_study ,business.industry ,Incidence ,Papillomavirus Infections ,Cancer ,General Medicine ,Vulvar cancer ,Middle Aged ,medicine.disease ,United States ,stomatognathic diseases ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Human papillomavirus (HPV) is a known cause of cervical cancer, as well as some oropharyngeal, vulvar, vaginal, penile, and anal cancers. To assess trends, characterized by average annual percent change (AAPC), in HPV-associated cancer incidence during 1999-2015, CDC analyzed data from cancer registries covering 97.8% of the U.S. Population A total of 30,115 new cases of HPV-associated cancers were reported in 1999 and 43,371 in 2015. During 1999-2015, cervical cancer rates decreased 1.6% per year; vaginal squamous cell carcinoma (SCC) rates decreased 0.6% per year; oropharyngeal SCC rates increased among both men (2.7%) and women (0.8%); anal SCC rates also increased among both men (2.1%) and women (2.9%); vulvar SCC rates increased (1.3%); and penile SCC rates remained stable. In 2015 oropharyngeal SCC (15,479 cases among men and 3,438 among women) was the most common HPV-associated cancer. Continued surveillance through high-quality cancer registries is important to monitor cancer incidence and trends in these potentially preventable cancers.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.